The outcome of resected cystic pancreatic endocrine neoplasms: A case-matched analysis

Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Surgery (Impact Factor: 3.37). 11/2011; 151(4):518-25. DOI: 10.1016/j.surg.2011.09.037
Source: PubMed

ABSTRACT Cystic pancreatic endocrine neoplasms (CPENs) are uncommon tumors with uncertain disease biology and ill-defined diagnostic features.
A prospectively maintained pancreatic cyst registry was queried, and 31 cases of CPEN that were resected between 1995 and 2010 were identified. Patient and lesion characteristics were detailed and compared with resected non-PEN cystic lesions. Recurrence and survival outcome were compared with 31 noncystic PENs matched for functional status, differentiation, size, World Health Organization classification, grade, and presence of metastases.
During the study period, CPENs accounted for 7% of resected pancreatic cysts (31/469) and 12% of resected PENs (31/255). CPENs were primarily sporadic (94%), solitary (87%), nonfunctioning (100%), and incidentally discovered (68%). The median diameter was 2.1 cm (range, 0.9-6.2 cm), and preoperative imaging identified septations in 29%, a solid component in 26%, and cyst wall enhancement or a characteristic hypervascular rim in 45% of cases. Preoperative imaging and/or cytology suggested the diagnosis of CPEN in 61%. Compared with resected nonendocrine cystic lesions, CPEN were less frequently symptomatic, less likely to contain septations, and smaller. Compared with matched noncystic PENs, CPENs had comparable demographic, radiologic, and pathologic features and statistically similar long-term outcome (5-year disease-free survival: CPEN: 100% vs PEN: 86%, P = .947).
In this study, CPENs were primarily asymptomatic small lesions that could be characterized in the majority of cases by cyst wall enhancement on preoperative imaging and/or cytologic assessment. No significant difference in recurrence or survival outcome was identified between cystic and noncystic PENs.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction Cystic pancreatic neuroendocrine neoplasms (PNENs) are rare neoplasms and presently it is uncertain if their behavior is similar or distinct from their solid counterparts. This study aims to systematically review the present literature to compare the clinicopathological characteristics of cystic PNEN versus their solid counterparts to determine if cystic PNENs are likely to be a distinct entity from solid PNENs. Methods Comparative studies of solid versus cystic PNENs studies were reviewed. Cystic and solid PNENs were compared based on several clinicopathological characteristics. Results Seven non-randomized case control studies compared 152 cystic versus 915 solid PNENs. Pooled analysis demonstrated that the likelihood of PNENs to be located in the head/uncinate of the pancreas were significantly lower for cystic than solid neoplasms (27.7% vs 45.5%, OR = 0.452, 95% CI = 0.304 to 0.673, P < 0.001). Cystic PNENs were significantly less likely to be functional (14% vs 24.4%, OR = 0.405, 95% CI = 0.221 to 0.742, P = 0.003) and were more likely to be benign/uncertain rather than malignant compared to solid PNENs (90.3% vs 65.9%, OR = 3.151, 95% CI = 1.297 to 7.652, P = 0.011). Cystic PNENs were significantly more likely to have a mitotic count < 2 per 10 hpf and a Ki67 index < 2% (93.3% vs 72.7%, OR 4.897,95% CI = 2.139 to 11.209 , p< 0.001 and 82.4% vs 54.1%, OR 4.079, 95% CI =2.177 to 7.641, p<0.001 ) respectively. Cystic neoplasms were also significantly less likely to have regional lymph node metastases than solid neoplasms (11.2% vs 28.9%, OR = 0.387, 95% CI = 0.219 to 0.685, P = 0.001). In this meta-analysis, there was no difference in the 5-year OS and 5-yr DFS between cystic vs solid PNENs (92.0% vs 86.8%, p 0.214) and (98.1% vs 83.9%, p= 0.185). Conclusion These findings suggested that cystic PNENs tended to be biologically less aggressive when compared to their solid counterparts. However more data with respect to molecular analysis would be required to establish if cystic and solid PNENs were distinct pathological entities.
    Surgery 07/2014; DOI:10.1016/j.surg.2014.03.026 · 3.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic cystic neoplasms (PCNs) are a heterogeneous group of tumors with distinct biological features. These neoplasms are now being recognized more frequently due to advances in cross-sectional imaging and increasing awareness. Guidelines for treatment of the common and clinically important PCNs have been frequently revised in view of the continuing controversies and evolving clinical data. This review summarizes the management approaches of the common and clinically important PCNs based on current evidence and guidelines.
    Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 08/2013; 12(1). DOI:10.1016/j.cgh.2013.08.031 · 5.64 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Approximately 10% of persons 70 years old or older are now diagnosed with pancreatic cysts, but it is not clear which ones require additional analysis, interventions, or follow-up. Primary care doctors rely on gastroenterologists for direction because no one wants to miss a diagnosis of pancreatic cancer, but meanwhile there is pressure to limit use of diagnostic tests and limit costs. We review the different cystic neoplasms of the pancreas and diagnostic strategies based on clinical features and imaging data. We discuss surgical and nonsurgical management of the most common cystic neoplasms, based on the recently revised Sendai guidelines. Intraductal papillary mucinous neoplasm (particularly the branch duct variant) is the lesion most frequently identified incidentally. We report what is known about its pathology, its risk of developing into pancreatic ductal adenocarcinoma, the pros and cons of current guidelines for management, and the potential role of endoscopic ultrasound in determining cancer risk. We also review surgical treatment and strategies for surveillance of pancreatic cysts.
    Gastroenterology 06/2013; 144(6):1303-15. DOI:10.1053/j.gastro.2013.01.073 · 12.82 Impact Factor